Well Researched

Sermorelin

GHRH 1-29 Analog | Growth Hormone Releasing Hormone

Sermorelin acetate is a 29-amino acid synthetic analog of human growth hormone-releasing hormone (GHRH) originally FDA-approved in 1997 for pediatric growth hormone deficiency. Despite discontinuation in 2008 for manufacturing reasons, it maintains excellent safety profile and stimulates natural growth hormone production while preserving physiological pulsatile patterns.

Daily dose

200-300 mcg

Frequency

Once daily

Cycle length

3-6 months

Storage

2-8°C

Key benefits

FDA-proven efficacy, 6% bioavailability, maintains natural GH pulses, preserves pituitary function

How it works

Subcutaneous injection provides optimal bioavailability with rapid onset (5-20 minutes) and physiological pulsatile GH stimulation

Dosage protocols

Goal

Anti-aging/Longevity

Dose

200-300 mcg daily · Once at bedtime

Route

Subcutaneous injection

Goal

Athletic Performance

Dose

300-500 mcg daily · Once at bedtime

Route

Subcutaneous injection

Goal

Pediatric GH Deficiency

Dose

30 mcg/kg daily · Once at bedtime

Route

Subcutaneous injection

Goal

Diagnostic Testing

Dose

1 mcg/kg IV · Single dose

Route

Intravenous bolus

Goal

Body Composition

Dose

200 mcg daily · 5 days weekly

Route

Subcutaneous injection

Goal

Combination Therapy

Dose

200 mcg + GHRP · Once daily

Route

Subcutaneous co-injection

Research indications

muscle Growth

Lean Body Mass Enhancement — 1.26 kg lean mass increase documented in elderly men with improved muscle strength tests

IGF-1 Mediated Growth — Stimulates endogenous IGF-1 production leading to muscle protein synthesis and growth

Athletic Performance Support — Enhanced recovery and muscle development through physiological GH stimulation

anti Aging

Age-Related GH Decline Reversal — Restores GH/IGF-1 levels approaching those of younger men in 60-78 year old subjects

Body Composition Improvement — Decreased adiposity and enhanced muscle-to-fat ratios in clinical studies

Skin Thickness Enhancement — GH-mediated improvements in skin quality and thickness documented in aging studies

hormonal

Endogenous GH Stimulation — Stimulates body's own GH production while preserving hypothalamic-pituitary axis integrity

Natural Pulsatile Patterns — Maintains physiological GH secretion patterns unlike direct HGH square-wave exposure

Preserved Feedback Regulation — Allows natural somatostatin negative feedback to maintain homeostasis

Administration

injectable

nasal

Interactions

Synergistic

Ipamorelin — Excellent combination producing 3-5 fold increases in GH release. GHRH and GHRP work through different pathways with proven synergistic effects in clinical studies.

Synergistic

CJC-1295 — Highly effective combination - CJC-1295 provides sustained 6-8 day release while sermorelin offers immediate pulsatile effects. Commonly dosed together in clinical protocols.

Synergistic

GHRP-2 — Combined GHRH+GHRP-2 produces 54-fold GH increases compared to 20-fold with GHRH alone. Well-documented synergistic mechanism.

Avoid Combination

Octreotide — Somatostatin analogs directly block GH release by activating inhibitory somatostatin receptors, completely negating sermorelin therapeutic effects.

Avoid Combination

Lanreotide — Another somatostatin analog that inhibits GH release through direct receptor antagonism, making combination with sermorelin counterproductive.

Use Caution

Prednisone — High-dose glucocorticoids suppress pituitary GH release and reduce GHRH receptor sensitivity. Requires dose adjustments and IGF-1 monitoring.

Monitor Combination

Insulin — GH antagonizes insulin action through IGF-1-mediated effects. Monitor blood glucose and consider insulin dose adjustments during sermorelin therapy.

Compatible

Thyroid Hormones — Essential combination as untreated hypothyroidism prevents sermorelin response. 6.5% of patients develop hypothyroidism requiring hormone replacement.

Safety notes

Monitor thyroid function - 6.5% develop hypothyroidism requiring hormone replacement

Check IGF-1 levels monthly initially, then every 3-6 months long-term

Injection site reactions occur in 16.7% of patients but are generally mild

Contraindicated in active malignancy, pituitary tumors, and pregnancy

Research studies

Nasal Administration Study (1990s)

Adults | 30+ μg/kg intranasal | Acute | 69% patient preference over injection

Clinical study demonstrating effective nasal delivery with patient preference benefits and direct absorption via nasal capillaries

View study →

Synergistic Effects with GHRP-2 (Clinical)

Adults | GHRH+GHRP-2 | Acute | 54-fold vs 20-fold GH increase

Study demonstrating significant synergistic effects when combining GHRH analogs with growth hormone releasing peptides

View study →

FDA Approval Study - Pediatric GH Deficiency (1996)

Children | 30 mcg/kg daily | 36 months | Height velocity 4.1→8.0 cm/year

Pivotal Geref International Study Group trial with 110 prepubertal GH-deficient children demonstrating sustained efficacy through 36 months of treatment

View study →

Pharmacokinetic Profile Study (1996)

Adults | Single dose | Acute | 11-12 minute half-life, 6% bioavailability

Comprehensive pharmacokinetic analysis showing rapid clearance and bioavailability profile for subcutaneous administration

View study →

Adult Anti-Aging Study - Elderly Men (1992)

Men aged 60-78 | Variable doses | 6 weeks | Doubled 12-hour GH release

Landmark study by Corpas et al. demonstrating reversal of age-related GH/IGF-1 decline with improvements approaching younger men

View study →

Body Composition in Elderly (1992)

Men 60-78 years | Multiple doses | 6 weeks | 1.26 kg lean mass increase

Study by Vittone et al. showing improved muscle strength tests, decreased systolic blood pressure, and enhanced body composition

View study →

Related compounds

Tesamorelin CJC-1295 (without DAC)CJC-1295 (no DAC) / Ipamorelin Protocol HGH (Somatropin)